Technical Analysis for AERI - Aerie Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 17.39 0.81% 0.14
AERI closed up 0.81 percent on Monday, April 19, 2021, on 74 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical AERI trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.81%
20 DMA Resistance Bearish -2.96%
Fell Below 50 DMA Bearish -2.96%
Fell Below 20 DMA Bearish -5.18%
MACD Bearish Centerline Cross Bearish -5.18%
50 DMA Support Bullish -6.81%
Crossed Above 20 DMA Bullish -6.81%
MACD Bullish Centerline Cross Bullish -6.81%
Older End-of-Day Signals for AERI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 17 hours ago
Down 1% about 18 hours ago
Fell Below Previous Day's Low about 18 hours ago
Trending on StockTwits about 21 hours ago
Down 3% 4 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its product candidates include dual-action AR-13324, a once-daily eye drop to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension, which has completed a Phase IIb clinical trials; triple-action PG324, a single drop fixed-dose combination of AR-13324 and latanoprost for the treatment of patients with glaucoma; and AR-13533, a dual-action ROCK/NET inhibitor that is in preclinical development stage. The company was founded in 2005 and is headquartered in Bedminster, New Jersey.
Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Pharmaceutical Diseases Clinical Development Eye Chemical Compounds Organic Compounds Hypertension Stage Pharmaceutical Alcohols Glaucoma Cyclopropanes Bedminster Intraocular Pressure Ocular Hypertension Prostaglandins

Is AERI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.3
52 Week Low 9.01
Average Volume 560,271
200-Day Moving Average 14.05
50-Day Moving Average 18.22
20-Day Moving Average 18.14
10-Day Moving Average 18.12
Average True Range 1.04
ADX 21.73
+DI 14.32
-DI 26.36
Chandelier Exit (Long, 3 ATRs ) 17.30
Chandelier Exit (Short, 3 ATRs ) 19.53
Upper Bollinger Band 19.39
Lower Bollinger Band 16.88
Percent B (%b) 0.2
BandWidth 13.84
MACD Line -0.18
MACD Signal Line -0.06
MACD Histogram -0.1211
Fundamentals Value
Market Cap 814.11 Million
Num Shares 46.8 Million
EPS -5.17
Price-to-Earnings (P/E) Ratio -3.36
Price-to-Sales 7.02
Price-to-Book 9.92
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.14
Resistance 3 (R3) 18.06 17.73 18.02
Resistance 2 (R2) 17.73 17.54 17.77 17.97
Resistance 1 (R1) 17.56 17.42 17.65 17.64 17.93
Pivot Point 17.23 17.23 17.27 17.27 17.23
Support 1 (S1) 17.06 17.04 17.15 17.14 16.85
Support 2 (S2) 16.73 16.92 16.77 16.81
Support 3 (S3) 16.56 16.73 16.77
Support 4 (S4) 16.64